Decisions / 4808
final resolution2021-05-06active

Arzneimittel-Richtlinie/Anlage XII: Baricitinib (neues Anwendungsgebiet: mittelschwere bis schwere atopische Dermatitis)

Open official decision page ↗

G-BA source · retrieved 2026-08-05

Structured conclusion

Final result by patient group

1 source-verified result

Patient group

Erwachsene Patienten mit mittelschwerer bis schwerer atopischer Dermatitis, die für eine kontinuierliche systemische Therapie infrage kommen

Added benefit not proven

Comparator
Dupilumab (ggf. in Kombination mit topischen Glukokortikoiden (TCS) und/oder topischen Calcineurininhibitoren (TCI))

Open official result PDF ↗

Decision orientation

What the G-BA did

4 cited claims

Each claim links to the official G-BA page or an exact PDF page range.

Official metadata

Decision date
2021-05-06
Effective
06.05.2021
Action type
final resolution
Committee
Arzneimittel

Case context

Listed normative targets

directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V

A listed target is not treated as a new directive version unless an official version source exists.

Official document package